A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

BACKGROUND: Although FOLFIRINOX is currently one of the standard therapies for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC), the high rate of febrile neutropenia (FN) presents a clinical problem. This study aimed to evaluate the safety and efficacy of primary prophylactic pegf...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Mitsuhito, Ueno, Hideki, Mitsunaga, Shuichi, Ohba, Akihiro, Hosoi, Hiroko, Kobayashi, Satoshi, Ueno, Makoto, Terazawa, Tetsuji, Goto, Masahiro, Inoue, Dai, Namiki, Shin, Sakamoto, Yasunari, Kondo, Shunsuke, Morizane, Chigusa, Ikeda, Masafumi, Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520880/
https://www.ncbi.nlm.nih.gov/pubmed/34368921
http://dx.doi.org/10.1007/s10147-021-02001-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520880/
https://www.ncbi.nlm.nih.gov/pubmed/34368921
http://dx.doi.org/10.1007/s10147-021-02001-y

Ejemplares similares